Continuing Medical Education
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this live activity for a maximum of 27.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by November 27, 2023. Certificates will only be issued to those who complete the survey. The Request for Credit Survey is available on the ACCR Website and via email. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 27.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.
Statement of Educational Need, Target Audience, and Learning Objectives
The conference addresses the need for researchers and clinicians from academia, industry, and government to keep pace with the rapid advancement of molecular biology and genetics, the consequent emergence of new targets for cancer therapeutics, and the opportunities presented by immunotherapy, combination therapies, novel trial designs, and new technologies on treatment and delivery.
Molecularly targeted therapies have achieved great success from the “early days” of selective estrogen receptor modulators and aromatase inhibitors to more recent developments in signal transduction, histone deacetylases, and proteasome inhibitors. However, for each of these success stories, new challenges arise in terms of resistance, further refinement of these “targeted therapies” based on molecular sub-classification, and the opportunity to develop new combination therapies, especially with new immunotherapies.
Targeted cancer therapeutics allow practicing clinicians to tailor cancer treatment, especially when a target is present in some but not all tumors of a particular type. Many researchers focus their efforts on the unique set of molecular targets produced by the patient’s tumor, regardless of disease site. Targeted cancer therapies hold the promise of being more selective for cancer cells than normal cells, thus harming fewer normal cells, reducing side effects, and improving quality of life for patients.
Attendees at this program will be presented with the latest research in the areas of antibody drug conjugates, CDK inhibitors, DDR, glycobiology, KRAS, liquid biopsies, mRNA and vaccines, patient-derived models, therapeutic advances targeting p53, tumor agnostic drug development, tumor heterogeneity, and more scheduled to be presented during the conference.
The conference will provide an educational and informative program that features a variety of topics related to targeted therapeutic development which have the potential to impact patient care strategies and decision-making. The conference allows international experts to share their research that may have application across many disease sites with a diverse set of stakeholders – from academia, government, industry, funders, and the press. Education, interaction, and communication among these different stakeholders is critical in the development and deployment of any new therapeutic or combination treatment strategy.
After participating in this CME activity, physicians should be able to:
- Articulate the rationale and identify best practices for tumor-agnostic clinical trial design and drug development.
- Assess the emerging role of vaccines and mRNA in cancer prevention and treatment.
- Explain the advantages and challenges of large-scale, multi-center clinical trials in oncology drug development.
- Identify recent developments made in the design and development of antibody drug conjugates and their application for patient care.
- Provide an overview of the recent successes of targeting the RAS pathway and a historical perspective of this previously “undruggable” pathway.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships for these individuals have been mitigated.
Acknowledgment of Financial or Other Support
The AACR gratefully acknowledges the following commercial supporters for their Professional Educational Grants: